Hepatocellular adenoma (HCA) in the pediatric population is very rare and there are only limited studies, especially with molecular characterization of the tumors. Main HCA subtypes recognized in the current WHO classification include HNF1A-inactivated HCA (H-HCA), inflammatory HCA (IHCA), β-catenin-activated HCA (b-HCA), and β-catenin-activated IHCA (b-IHCA) and sonic hedgehog HCA (shHCA) is reported as an emerging subtype.
Methods:
Clinical history, pathological information, and molecular studies for a series of 2 cases of pediatric HCA were reviewed.
Results:
Case 1 was a b-HCA characterized by somatic CTNNB1 S45 mutation in a 11-year-old male with Abernethy malformation. Case 2 was a H-HCA characterized by germline HNF1A variant (c.526+1G>A) in a 15-year-old male associated with maturity-onset diabetes of the young type 3 (MODY3).
Conclusion:
Our findings highlight the rarity of these 2 cases associated with adenomatosis, and the contribution of molecular/genetic analysis for proper sub-typing, prognosis and family surveillance.
NagtegaalIDOdzeRDKlimstraD, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-188. doi:10.1111/his.13975
BeaufrereAParadisV.Hepatocellular adenomas: review of pathological and molecular features. Hum Pathol. 2021;112:128-137. doi:10.1016/j.humpath.2020.11.016
4.
JeannotEMellotteeLBioulac-SageP, et al. Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage. Diabetes. 2010;59(7):1836-1844. doi:10.2337/db09-1819
5.
Bioulac-SagePRebouissouSThomasC, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007;46(3):740-748. doi:10.1002/hep.21743
6.
SaldarriagaJBisigBCouchyG, et al. Focal beta-catenin mutation identified on formalin-fixed and paraffin-embedded inflammatory hepatocellular adenomas. Histopathology. 2017;71(6):989-993. doi:10.1111/his.13283
7.
LisovskyMKonstasAAMisdrajiJ.Congenital extrahepatic portosystemic shunts (Abernethy malformation): a histopathologic evaluation. Am J Surg Pathol. 2011;35(9):1381-1390. doi:10.1097/PAS.0b013e3182230ce4
8.
MuthuvelEChanderVSrinivasanC.A clinicopathological study of paediatric liver tumours in a tertiary care hospital. J Clin Diagn Res. 2017;11(3):EC50-EC53. doi:10.7860/JCDR/2017/24223.9592
9.
PachecoMCTorbensonMSWuTTKakarSJainDYehMM.Pediatric hepatocellular adenomas: the influence of age and syndrome on subtype. Am J Surg Pathol. 2021;45(12):1641-1647. doi:10.1097/PAS.0000000000001763
10.
LeeseTFargesOBismuthH.Liver cell adenomas. A 12-year surgical experience from a specialist hepato-biliary unit. Ann Surg. 1988;208(5):558-564. doi:10.1097/00000658-198811000-00003
11.
GonzalezIASurreyLFRussoP.Hepatocellular adenoma in an infant with Burn-McKeown syndrome: report of a case. Pediatr Dev Pathol. 2022;25(6):668-671. doi:10.1177/10935266221109468
12.
Franchi-AbellaSBranchereauS.Benign hepatocellular tumors in children: focal nodular hyperplasia and hepatocellular adenoma. Int J Hepatol. 2013;2013:215064. doi:10.1155/2013/215064
13.
FabreMYilmazFBuendiaMA.Les tumeurs hepatiques de l’enfant: experience a propos de 245 tumeurs et revue de la litterature [Hepatic tumors in childhood: experience on 245 tumors and review of literature]. Ann Pathol. 2004;24(6):536-555. doi:10.1016/s0242-6498(04)94017-5
14.
DaulehHSolimanAHarisBKhalifaAAl KhoriNHussainK.Case report: hepatic adenomatosis in a patient with Prader-Willi syndrome. Front Endocrinol. 2022;13:826772. doi:10.3389/fendo.2022.826772
15.
BergSAraujo PerezT.Giant HNF 1alpha-inactivated liver adenoma in a nine-year-old boy with abernethy malformation Type II. Rofo. 2021;193(1):84-87. doi:10.1055/a-1207-0935
16.
DiPaolaFTroutATWaltherAE, et al. Congenital portosystemic shunts in children: associations, complications, and outcomes. Dig Dis Sci. 2020;65(4):1239-1251. doi:10.1007/s10620-019-05834-w
17.
LiuYZenYYehMM.Steatohepatitis-like changes in hepatocellular adenoma. Am J Clin Pathol. 2020;154(4):525-532. doi:10.1093/ajcp/aqaa075
18.
HetzerBVogelGFEntenmannA, et al. Stereotactic radiofrequency ablation of a variety of liver masses in children. Int J Hyperthermia. 2020;37(1):1074-1081. doi:10.1080/02656736.2020.1822549
19.
OkataYHatakeyamaTBitohYAidaYYuichiroT.Hepatocellular carcinoma with glycogen storage disease type 1a. Pediatr Int. 2020;62(6):744-745. doi:10.1111/ped.14202
20.
SinghHKPatkarSPolnayaAMRamadwarMGoelM.Giant hepatic adenoma in a 12-year-old girl. J Gastrointest Cancer. 2019;50(1):156-159. doi:10.1007/s12029-017-9999-5
21.
WangWYuRTanWDanYDengGXiaJ.A patient with glycogen storage disease type Ia combined with chronic hepatitis B infection: a case report. BMC Med Genet. 2019;20(1):85. doi:10.1186/s12881-019-0816-9
22.
PachecoMCMonroeEJHorslenSP.Hepatic adenoma arising in a patient with alagille syndrome: a case report. Pediatr Dev Pathol. 2018;21(6):585-589. doi:10.1177/1093526618762550
23.
BattagliaACalhounALortzACareyJC.Risk of hepatic neoplasms in Wolf-Hirschhorn syndrome (4p-): Four new cases and review of the literature. Am J Med Genet A. 2018;176(11):2389-2394. doi:10.1002/ajmg.a.40469
24.
BradyPCMissmerSALauferMR.Hepatic adenomas in adolescents and young women with endometriosis treated with norethindrone acetate. J Pediatr Adolesc Gynecol. 2017;30(3):422-424. doi:10.1016/j.jpag.2016.12.002
25.
LouieCYConcepcionWParkJKRangaswamiAFinegoldMJHazardFK.Hepatoblastoma arising in a pigmented beta-catenin-activated hepatocellular adenoma: case report and review of the literature. Am J Surg Pathol. 2016;40(7):998-1003. doi:10.1097/PAS.0000000000000652
26.
RosencrantzRAWuYSonkePYYusufY.Giant hepatocellular adenoma in a previously obese thirteen-year-old boy. Ann Hepatol. 2015;14(4):559-563.
27.
QureshiSSBhagatMKembhaviS, et al. Benign liver tumors in children: outcomes after resection. Pediatr Surg Int. 2015;31(12):1145-1149. doi:10.1007/s00383-015-3763-3
28.
SanadaYMizutaKNikiT, et al. Hepatocellular nodules resulting from congenital extrahepatic portosystemic shunts can differentiate into potentially malignant hepatocellular adenomas. J Hepatobiliary Pancreat Sci. Oct2015;22(10):746-56. doi:10.1002/jhbp.277
29.
FelstedAEShiYMasandPMNuchternJGGossJAVasudevanSA.Intraoperative ultrasound for liver tumor resection in children. J Surg Res. 2015;198(2):418-423. doi:10.1016/j.jss.2015.03.087
30.
YadavRMallickSMittalD, et al. Giant hepatocellular adenoma with peliosis hepatis in a child: A diagnostic dilemma. Trop Gastroenterol. 2015;36(3):200-202. doi:10.7869/tg.287
31.
McDanielJDKukrejaKRistagnoRLYazigiNNathanJDTiaoG.Radiofrequency ablation of a large hepatic adenoma in a child. J Pediatr Surg. 2013;48(6):E19-E22. doi:10.1016/j.jpedsurg.2013.04.007
32.
BaliDSGoldsteinJLFredricksonK, et al. Variability of disease spectrum in children with liver phosphorylase kinase deficiency caused by mutations in the PHKG2 gene. Mol Genet Metab. 2014;111(3):309-313. doi:10.1016/j.ymgme.2013.12.008
33.
RonaldiAEHairstonFJGilesHWNowickiMJ.Giant hepatocellular adenoma in a child. Dig Liver Dis. 2014;46(3):287. doi:10.1016/j.dld.2013.08.135
34.
RoscherAPatelJHewsonS, et al. The natural history of glycogen storage disease types VI and IX: Long-term outcome from the largest metabolic center in Canada. Mol Genet Metab. 2014;113(3):171-176. doi:10.1016/j.ymgme.2014.09.005
MorrisMWBerchBWestmorelandTSawayaDEBlewettCJ.Resection of a giant hepatic adenoma in an eight-year-old girl. Am Surg. 2013;79(9):889-890.
37.
LaganaSMSalomaoMBaoFMoreiraRKLefkowitchJHRemottiHE.Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma. Appl Immunohistochem Mol Morphol. 2013;21(2):170-176. doi:10.1097/PAI.0b013e31825d527f
38.
JacobJDeganelloASellarsMEHadzicNSidhuPS.Contrast enhanced ultrasound (CEUS) characterization of grey-scale sonographic indeterminate focal liver lesions in pediatric practice. Ultraschall Med. 2013;34(6):529-540. doi:10.1055/s-0033-1355785
39.
SakellariouSAl-HussainiHScaloriA, et al. Hepatocellular adenoma in glycogen storage disorder type I: a clinicopathological and molecular study. Histopathology. 2012;60(6B):E58-E65. doi:10.1111/j.1365-2559.2011.04153.x
40.
CerminaraCBagnoloVDe LeonardisF, et al. Hepatocellular adenoma associated with long-term exposure to phenobarbital: a paediatric case report. Childs Nerv Syst. 2012;28(6):939-941. doi:10.1007/s00381-011-1636-1
41.
BaigesATuronFSimon-TaleroM, et al. Congenital extrahepatic portosystemic shunts (abernethy malformation): an international observational study. Hepatology. 2020;71(2):658-669. doi:10.1002/hep.30817
42.
TyraskisADavenportMDeganelloA, et al. Complications of congenital portosystemic shunts: liver tumors are affected by shunt severity, but pulmonary and neurocognitive associations are not. Hepatol Int. 2022;16(4):918-925. doi:10.1007/s12072-022-10328-5
43.
SorkinTStrautnieksSFoskettP, et al. Multiple beta-catenin mutations in hepatocellular lesions arising in abernethy malformation. Hum Pathol. 2016;53:153-158. doi:10.1016/j.humpath.2016.02.025
44.
LautzTBShahSASuperinaRA.Hepatoblastoma in children with congenital portosystemic shunts. J Pediatr Gastroenterol Nutr. 2016;62(4):542-545. doi:10.1097/MPG.0000000000001012
45.
SharmaRSuddleAQuagliaA, et al. Congenital extrahepatic portosystemic shunt complicated by the development of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015;14(5):552-557. doi:10.1016/s1499-3872(15)60418-0
46.
Zucman-RossiJJeannotENhieuJT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43(3):515-524. doi:10.1002/hep.21068
47.
HaringMPDElfrinkAKEOudmaijerCAJ, et al. A nationwide assessment of hepatocellular adenoma resection: Indications and pathological discordance. Hepatol Commun. 2023;7(1):e2110. doi:10.1002/hep4.2110
48.
RebouissouSFranconiACalderaroJ, et al. Genotype-phenotype correlation of CTNNB1 mutations reveals different ss-catenin activity associated with liver tumor progression. Hepatology. 2016;64(6):2047-2061. doi:10.1002/hep.28638
49.
NaultJCCouchyGBalabaudC, et al. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology. 2017;152(4):880-894 e6. doi:10.1053/j.gastro.2016.11.042
50.
PilatiCLetouzeENaultJC, et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell. 2014;25(4):428-441. doi:10.1016/j.ccr.2014.03.005
51.
Bioulac-SagePLaumonierHCouchyG, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology. 2009;50(2):481-489. doi:10.1002/hep.22995
52.
European Association for the Study of the L. EASL Clinical Practice Guidelines on the management of benign liver tumours. J Hepatol. 2016;65(2):386-398. doi:10.1016/j.jhep.2016.04.001
53.
SempouxCGouwASHDunetVParadisVBalabaudCBioulac-SageP.Predictive patterns of glutamine synthetase immunohistochemical staining in CTNNB1-mutated hepatocellular adenomas. Am J Surg Pathol. 2021;45(4):477-487. doi:10.1097/PAS.0000000000001675
54.
Alonso-GamarraEParronMPerezAPrietoCHierroLLopez-SantamariaM.Clinical and radiologic manifestations of congenital extrahepatic portosystemic shunts: a comprehensive review. Radiographics. 2011;31(3):707-722. doi:10.1148/rg.313105070
55.
HabebAMGeorgeETMathewVHattersleyAL.Response to oral gliclazide in a pre-pubertal child with hepatic nuclear factor-1 alpha maturity onset diabetes of the young. Ann Saudi Med. 2011;31(2):190-193. doi:10.4103/0256-4947.75590
56.
FraylingTMEvansJCBulmanMP, et al. Beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors. Diabetes. 2001;50(Suppl 1):S94-S100. doi:10.2337/diabetes.50.2007.s94
57.
FuJWangTZhaiXXiaoX.Primary hepatocellular adenoma due to biallelic HNF1A mutations and its co-occurrence with MODY 3: case-report and review of the literature. Endocrine. 2020;67(3):544-551. doi:10.1007/s12020-019-02138-x
58.
BluteauOJeannotEBioulac-SageP, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet. 2002;32(2):312-315. doi:10.1038/ng1001
59.
ReznikYDaoTCoutantR, et al. Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J Clin Endocrinol Metab. 2004;89(3):1476-1480. doi:10.1210/jc.2003-031552
60.
IwenKAKleinJHuboldCLehnertHWeitzelJM.Maturity-onset diabetes of the young and hepatic adenomatosis - characterisation of a new mutation. Exp Clin Endocrinol Diabetes. 2013;121(6):368-3671. doi:10.1055/s-0033-1341519
61.
AcarAHidalgo-SastreALeverentzMK, et al. Inhibition of Wnt signalling by Notch via two distinct mechanisms. Sci Rep. 2021;11(1):9096. doi:10.1038/s41598-021-88618-5
62.
WillsonJSGodwinTDWigginsGAGuilfordPJMcCallJL.Primary hepatocellular neoplasms in a MODY3 family with a novel HNF1A germline mutation. J Hepatol. 2013;59(4):904-907. doi:10.1016/j.jhep.2013.05.024
63.
StueckAEQuZHuangMACampreciosGFerrellLDThungSN.Hepatocellular carcinoma arising in an HNF-1alpha-mutated adenoma in a 23-year-old woman with maturity-onset diabetes of the young: a case report. Semin Liver Dis. 2015;35(4):444-449. doi:10.1055/s-0035-1567827
